Preclinical sepsis models

Surgical Infections

Volumn 13, Issue 5, 2012, Pages 287-292

  Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; ANTITHROMBIN; BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; INTERLEUKIN 1; PROTEIN C; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABDOMINAL INFECTION; ARTICLE; BACTERIAL LOAD; BACTERIAL PERITONITIS; BACTERIAL VIRULENCE; COMORBIDITY; CYTOKINE PRODUCTION; DISEASE MODEL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG MECHANISM; DRUG USE; ENDOTOXEMIA; ESCHERICHIA COLI; GRAM NEGATIVE SEPSIS; HEREDITY; HOSPITAL ACQUIRED PNEUMONIA; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IN VITRO STUDY; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERITONEAL CAVITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; SEPSIS;

EID: 84869840966     PISSN: 10962964     EISSN: 15578674     Source Type: Journal    
DOI: 10.1089/sur.2012.105     Document Type: Article

References (46)

1. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM Consensus Conference on sepsis and organ failure. Chest 1992; 101:1481-1483.
2. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008;8:32-43.
3. Fry DE. Sepsis, systemic inflammatory response, and multiple organ dysfunction: The mystery continues. Am Surg 2012;78:1-8.
4. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330:662-664. (Pubitemid 18005583)
5. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992;89: 1551-1557.
6. Skrupky LP, Kerby PW, Hotchkiss RS. Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology 2011;115:1349-1362.
7. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res 1990;49:186-196. (Pubitemid 20241651)
8. Deitch EA. Animal models of sepsis and shock: A review and lessons learned. Shock 1998;9:1-11. (Pubitemid 128463868)
9. Schultz MJ, van der Poll T. Animal and human models for sepsis. Ann Med 2002;34:573-581. (Pubitemid 36113816)
10. Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: Setting the stage. Nat Rev Drug Discov 2005;4: 854-865. (Pubitemid 41553966)
11. Poli-de-Figueiredo LF, Garrido AG, Nakagawa N, Sannomiya P. Experimental models of sepsis and their clinical relevance. Shock 2008;30(Suppl 1):S53-S59.
12. Dyson A, Singer M. Animal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009;37(Suppl 1):S30-S37.
13. Doi K, Leelahavanichkul A, Yuen PS, Star RA. Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest 2009;119:2868-2878.
14. Opal SM, Scannon PJ, Vincent JL, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180:1584-1589. (Pubitemid 29506461)
15. Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study. J Infect Dis 2004;190:527-534. (Pubitemid 38982092)
16. Lorente JA, Marshall JC. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 2005;24(Suppl 1):S107-S119.
17. Fiuza C, Suffredini AF. Human models of innate immunity: Local and systemic inflammatory responses. J Endotoxin Res 2001;7:385-388. (Pubitemid 34048540)
18. Lowry SF. Human endotoxemia: A model for mechanistic insight and therapeutic targeting. Shock 2005;24(Suppl 1):S94-S100.
19. Van der Poll T. Experimental human sepsis models. Drug Discovery Today: Disease Models 2012;9:e3-e9.
20. Taylor FB Jr. Staging of the pathophysiologic responses of the primate microvasculature to Escherichia coli and endotoxin: Examination of the elements of the compensated response and their links to the corresponding uncompensated lethal variants. Crit Care Med 2001;29(Suppl 7):S78-S89.
21. van der Poll T. Immunotherapy of sepsis. Lancet Infect Dis 2001;1:165-174. (Pubitemid 33586050)
22. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010;38(Suppl 2):S26-S34.
23. Taylor FB Jr, Emerson TE Jr, Jordan R, et al. Antithrombin-III prevents the lethal effects of Escherichia coli infusion in baboons. Circ Shock 1988;26:227-235. (Pubitemid 18268347)
24. Taylor FB Jr, Chang A, Esmon CT, et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-925. (Pubitemid 17050920)
25. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709. (Pubitemid 32204987)
26. Angus DC. Drotrecogin alfa (activated).A sad final fizzle to a roller-coaster party. Crit Care 2012;16:107.
27. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064.
28. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006;34:344-353. (Pubitemid 43145611)
29. Torres A, Rello J. Update in community-acquired and nosocomial pneumonia 2009. Am J Respir Crit Care Med 2010; 181:782-787.
30. Knapp S, Schultz MJ, van der Poll T. Pneumonia models and innate immunity to respiratory bacterial pathogens. Shock 2005;24(Suppl 1):S12-S18.
31. Steinhauser ML, Hogaboam CM, Kunkel SL, et al. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;162:392-399. (Pubitemid 29018946)
32. Deng JC, Cheng G, Newstead MW, et al. Sepsis-induced suppression of lung innate immunity is mediated by IRAKM. J Clin Invest 2006;116:2532-2542. (Pubitemid 44330152)
33. Prass K, Meisel C, Hoflich C, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med 2003;198:725-736. (Pubitemid 37087772)
34. Renckens R, van Westerloo DJ, Roelofs JJ, et al. Acute phase response impairs host defense against Pseudomonas aeruginosa pneumonia in mice. Crit Care Med 2008;36:580-587. (Pubitemid 351158636)
35. van Westerloo DJ, Schultz MJ, Bruno MJ, et al. Acute pancreatitis in mice impairs bacterial clearance from the lungs, whereas concurrent pneumonia prolongs the course of pancreatitis. Crit Care Med 2004;32:1997-2001. (Pubitemid 39372531)
36. Maier S, Traeger T, Entleutner M, et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: Two distinct animal models for polymicrobial sepsis. Shock 2004; 21:505-511.
37. Parker SJ, Watkins PE. Experimental models of gramnegative sepsis. Br J Surg 2001;88:22-30.
38. Dejager L, Pinheiro I, Dejonckheere E, Libert C. Cecal ligation and puncture: The gold standard model for polymicrobial sepsis? Trends Microbiol 2011;19:198-208.
39. van Zoelen MA, Achouiti A, Schmidt AM, et al. Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis. Crit Care Med 2010;38: 1414-1422.
40. Mathiak G, Szewczyk D, Abdullah F, et al. An improved clinically relevant sepsis model in the conscious rat. Crit Care Med 2000;28:1947-1952. (Pubitemid 30428756)
41. Goldfarb RD, Dellinger RP, Parrillo JE. Porcine models of severe sepsis: Emphasis on porcine peritonitis. Shock 2005;24(Suppl 1):S75-S81.
42. Rijneveld AW, Florquin S, Branger J, et al. TNF-alpha compensates for the impaired host defense of IL-1 type I receptor-deficient mice during pneumococcal pneumonia. J Immunol 2001;167:5240-5246. (Pubitemid 33009761)
43. Gerard C, Bruyns C,Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993;177:547-550. (Pubitemid 23117107)
44. van der Poll T, Marchant A, Keogh CV, et al. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000. (Pubitemid 26357461)
45. Levi M, van der Poll T. Recombinant human activated protein C: Current insights into its mechanism of action. Crit Care 2007;11(Suppl 5):S3.
46. Derhaschnig U, Reiter R, Knobl P, et al. Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003;102: 2093-2098. (Pubitemid 37122385)